Followers | 39 |
Posts | 1624 |
Boards Moderated | 0 |
Alias Born | 04/17/2012 |
Friday, February 13, 2015 12:53:47 PM
If you spend just a few minutes looking at the management and the boards past track record and accomplishments, it's not difficult to see where they may eventually be going with this.
While they have the DenerveX device that is targeted at a very large market, specifically Facet Joint Syndrome which I believe encompasses about 30% of all lower back pain, they also indicate they intend to make strategic acquisitions.
Makes perfect sense because when you look at the fact they have Dr. Andrews and other world renowned physicians on the board of directors, you could envision them providing an almost unlimited amount of opportunities for the company to consider. Because of who their board members are, they may get a first look at some of the best medtech opportunities in existence.
Bottom line, because of who is involved, there should be no shortage of potential "first look" opportunities being funneled in their deal pipeline. At some point, one could envision some of those opportunities, post being thoroughly vetted, coming out the other end in the form of some potential value creation.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM